The design of the study and treatment
This randomized, multicenter, placebo-controlled, double-blind, phase 3 study was conducted in 9 sites in China.The study entailed three periods: screening (up to 4 weeks), treatment (1 week), and post-treatment (4 weeks) (Supplementary material 1). Screening of likely patients who submitted written informed consent was done for PLT to scrutinize their eligibility, and the results were regarded as baseline data. Random allocation of eligible patients was done to lusutrombopag or placebo arm in a 2:1 ratio for the intake of one tablet a day of the study drug (3 mg of lusutrombopag or placebo)from first day of the treatment period for seven days. PLT was evaluated on Day 8 (the day after 7-day treatment) for primary endpoint analysis and then tested on Days 10, 15, 17, 21, 28, and 35. The planned procedure that was invasive was performed between days 9 and 15. If the PLT was < 50 × 10